CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), focused on therapies for chronic liver diseases, will participate in the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 9:00 am ET. This presentation marks a significant opportunity for CBAY to showcase its innovative pipeline, particularly its leading candidate, seladelpar, which has received breakthrough therapy designation for treating primary biliary cholangitis (PBC).
CymaBay is committed to addressing high unmet medical needs in liver health and chronic diseases. Its recent advancements have highlighted the potential of seladelpar in improving patient outcomes, supported by a rigorous understanding of liver disease mechanisms. For updates, visit their website at www.cymabay.com.
- None.
- None.
NEWARK, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ.
| H.C. Wainwright BioConnect Investor Conference at NASDAQ | ||
| Date: | Tuesday, May 2 | |
| Time: | 9:00 am Eastern Time | |
| Format: | Presentation | |
| Webcast: | http://ir.cymabay.com/events | |
About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on Twitter and Linkedin.
Cautionary Statements
Any statements made in this press release and at the conference referenced above regarding the potential for seladelpar to treat PBC and potentially improve clinical symptoms of the disease, the potential benefits to patients, and the timing of the release of seladelpar clinical data are forward-looking statements that are subject to risks and uncertainties. Actual outcomes and results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of product development activities; effects observed in trials to date that may not be repeated in the future; any delays or inability to obtain or maintain regulatory approval of product candidates; and the ability to obtain sufficient financing to complete development, regulatory approval and commercialization of product candidates. Additional risks relating to CymaBay are contained in CymaBay's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law.
For additional information about CymaBay visit www.cymabay.com.
Public Relations Contact:
Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com
Investor Relations Contact:
Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com
FAQ
When will CymaBay participate in the H.C. Wainwright BioConnect Investor Conference?
What time is CymaBay's presentation at the conference?
What is the primary focus of CymaBay Therapeutics?
What is seladelpar and its significance for CymaBay?
Where can I find more information about CymaBay Therapeutics?
